Edition:
United Kingdom

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

3.18USD
13 Dec 2018
Change (% chg)

-- (--)
Prev Close
$3.18
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
24,386
52-wk High
$39.00
52-wk Low
$3.18

Latest Key Developments (Source: Significant Developments)

Onconova Therapeutics Highlights Results From Phase 2 Trial Of Oral Rigosertib
Monday, 3 Dec 2018 

Dec 3 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA HIGHLIGHTS RESULTS FROM PHASE 2 TRIAL OF ORAL RIGOSERTIB IN COMBINATION WITH AZACITIDINE (VIDAZA®) IN MYELODYSPLASTIC SYNDROMES (MDS) AT THE 2018 ASH ANNUAL MEETING.ONCONOVA THERAPEUTICS INC - PIVOTAL PHASE 3 TRIAL IS PLANNED IN AN HMA AND CHEMOTHERAPY NAÏVE HIGHER RISK - MDS PATIENT POPULATION.ONCONOVA THERAPEUTICS INC - ORR OF 90% REPORTED IN PHASE 2 STUDY IN HYPOMETHYLATING AGENT NAÏVE PATIENTS, INCLUDING CR RATE OF 34%.ONCONOVA THERAPEUTICS INC - ORR OF 54% AND CR/PARTIAL RESPONSE OF 8% IN HMA FAILED PATIENTS REPORTED.ONCONOVA THERAPEUTICS INC - ORAL RIGOSERTIB IN COMBINATION WITH AZACITIDINE WAS WELL TOLERATED IN HMA NAÏVE AND HMA FAILED HR-MDS PATIENTS.  Full Article

Onconova Therapeutics Reports Q1 Loss Per Share Of $0.34
Tuesday, 15 May 2018 

May 15 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS FOR FIRST QUARTER 2018.ONCONOVA THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.34.  Full Article

Onconova Therapeutics Says Offering Up To 18.5 Mln Units Of Common Stock, Warrants
Tuesday, 17 Apr 2018 

April 17 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS - OFFERING UP TO 18.5 MILLION UNITS (UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT).  Full Article

Onconova Says Moving Forward With Pivotal Late-Stage Trial
Wednesday, 17 Jan 2018 

Jan 17 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS.ONCONOVA - DMC RECOMMENDS CONTINUATION OF INSPIRE TRIAL WITH TRIAL EXPANSION PER ADAPTIVE DESIGN BASED ON INTERIM ANALYSIS RESULTS FOR OS.ONCONOVA - TRIAL EXECUTIVE COMMITTEE UNANIMOUSLY AGREED TO CONTINUE INTENT TO TREAT STUDY POPULATION, INCREASE CLINICAL TRIAL ENROLLMENT.ONCONOVA - EXPANDED INSPIRE STUDY WILL INCREASE ENROLLMENT BY ADDING 135 PATIENTS TO ORIGINAL TARGET, TO REACH TOTAL ENROLLMENT OF 360 PATIENTS.  Full Article

Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE.ONCONOVA THERAPEUTICS - UNDER TERMS, NCI WILL CONDUCT RESEARCH ON RIGOSERTIB IN PEDIATRIC CANCER ASSOCIATED RASOPATHIES.  Full Article

Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Onconova Therapeutics Inc ::ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5.ONCONOVA THERAPEUTICS INC - HANX WILL FUND STUDIES TOWARDS INVESTIGATIONAL NEW DRUG APPLICATIONS IN BOTH U.S. AND CHINA.ONCONOVA THERAPEUTICS INC - AGREEMENT INCLUDES LICENSING FEE, CUSTOMARY MILESTONE PAYMENTS AND ROYALTIES ON SALES OF ON 123300.ONCONOVA THERAPEUTICS INC - HANX TO COMMERCIALIZE ON 123300 IN GREATER CHINA, ONCONOVA RETAINS RIGHTS IN REST OF WORLD.  Full Article

Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​.  Full Article

Onconova Therapeutics prices public offering
Friday, 10 Nov 2017 

Nov 10 (Reuters) - Onconova Therapeutics Inc :Onconova Therapeutics announces pricing of public offering of common stock.Agreed to sell approximately 920,000 shares of its common stock for gross proceeds of approximately $1.38 million​.Each share of common stock is being sold at a price of $1.50 per share​.  Full Article

Onconova Therapeutics reports Q3 revenue $100,000
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Onconova Therapeutics Inc :Onconova Therapeutics, Inc. reports business highlights and third quarter 2017 financial results.Q3 revenue $100,000 versus $1.7 million.Q3 revenue view $152,000 -- Thomson Reuters I/B/E/S.Onconova Therapeutics Inc - Qtrly loss per share $0.71.  Full Article